Pharmaceutical News

RSS

Joint statement to help patients, physicians make informed decisions about use of rosiglitazone

The Endocrine Society, American Diabetes Association and American Association of Clinical Endocrinologists issue joint statement in response to an FDA panel's recommendation to keep rosiglitazone (Avandia) on the market

16 Jul 2010

Treatment admissions for abuse of prescription pain relievers increases by over 400%: Study

The proportion of all substance abuse treatment admissions of those aged 12 and older involving abuse of prescription pain relievers rose by over 400 percent from 2.2 percent in 1998 to 9.8 percent in 2008 according to a new study be the Substance Abuse and Mental Health Services Administration (SAMHSA). This dramatic rise in the proportion of admissions associated with the abuse of these drugs occurred among nearly all segments of the population regardless of age, gender, educational level and employment status.

16 Jul 2010

LLC to provide contract drug development services

LyoTechnica, LLC has announced that it has been established to provide contract drug development services for injectable pharmaceuticals. The company and its affiliates bring over 80 years of combined experience in lyophilization and liquid dosage form development as well as over 100 years experience in commercial scale manufacturing of parenteral drugs. The company offers analytical and formulation development, manufacturing of sterile stability batches and stability testing services.

16 Jul 2010

FDA confirms GRAS status for Ajinomoto's AjiGRAS-Leucine

Ajinomoto AminoScience LLC (AAS) today announced that it has confirmed GRAS (Generally Recognized As Safe) status of its AjiGRAS-Leucine, meeting the safety standards demanded by the US Food and Drug Administration (FDA). As the only formulation of Leucine currently with FDA acknowledged GRAS status, Ajinomoto's AjiGRAS-Leucine is the first amino acid to be allowed as an ingredient for use in conventional foods like non-milk and milk based meal replacements, sports and isotonic beverages, vitamin enhanced waters, and meal replacement bars, at levels of 0.5 to 3 grams per serving.

16 Jul 2010

Steroid treatment can delay loss of kidney function

For patients with IgA nephropathy, a type of kidney disease, steroid treatment can prevent or delay loss of kidney function, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). IgA nephropathy is an autoimmune disease that affects the kidneys and a major cause of end-stage kidney failure in younger people

16 Jul 2010

Diamyd Medical receives US Federal Trade Commission's antitrust clearance

Diamyd Medical AB has received antitrust clearance that closes the transaction announced on June 22, 2010 with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), a Johnson & Johnson company.

16 Jul 2010

Neurologists more aware of Merck Serono/EMD Serono's oral cladribine than Novartis/Mitsubishi Tanabe's FTY-720

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed neurologists have low awareness of Novartis/Mitsubishi Tanabe's FTY-720 (Gilenia) among the surveyed oral emerging therapies for the treatment of multiple sclerosis (MS).

16 Jul 2010

First-of-its-kind patient, healthcare provider support program for management of HE

Concentric Pharma Advertising, an independent healthcare advertising and marketing agency, announces the creation of Salix Pharmaceuticals' Hepatic Encephalopathy Living Program. H.E.L.P. launched May 24, 2010, and coincides with the launch of Xifaxan550 (rifaximin) for the management of patients 18 or older at risk for overt hepatic encephalopathy recurrence.

16 Jul 2010

Federal advisory panel with reservations, recommends keeping Avandia on the Market

Federal advisers delivered a mixed verdict Wednesday on the diabetes drug Avandia,with a significant number of experts voting to recommend that it be pulled from the market because of safety concerns but a majority urging to keep it available, perhaps with tough new restrictions and new warnings.Avandia was once the world's most popular diabetes drugs but has become the focus of intense debate because of concerns that it increases the risk for heart attacks and strokes.

16 Jul 2010

Columbia scientists discover new way to alleviate chronic pain

Columbia scientists working to combat injury-related depression, substance abuse and suicide due to unremitting, persistent pain may have discovered a new way of treating that pain: a powerful analgesic dubbed N60 that leads to neither tolerance nor addiction.

16 Jul 2010

Judge says FTC likely overstepped authority in sharing drugmaker pay-for-delay info

A judge Wednesday criticized the Federal Trade Commission for the "strong possibility" that it "overstepped its bounds and shared confidential information" in a pay-for-delay case between the government and a generic drug company, Reuters reports.

16 Jul 2010

Arsenic nanoparticle to combat aggressive type of breast cancer prevalent in young women

You can teach an old drug new chemotherapy tricks. Northwestern University researchers took a drug therapy proven for blood cancers but ineffective against solid tumors, packaged it with nanotechnology and got it to combat an aggressive type of breast cancer prevalent in young women, particularly young African-American women.

16 Jul 2010

i26 hyperimmune egg balances improper immune inflammatory response

Our immune systems are in a constant battle with foreign invaders to keep our bodies healthy. Outside forces like pollution, poor nutrition and new strains of disease keep our immune systems at an overly boosted or inflamed state, which affects energy levels, body and emotional health and overall quality of life. Through inflammatory immune cells, our bodies fight to defend us from this onslaught. Too few of these cells can result in illness, while too many could lead to a high immune response, resulting in heightened inflammation and collateral damage to the body's once-healthy tissues.

16 Jul 2010

ACTOS offers safety profile regarding risk of CV events in people with type 2 diabetes: Takeda

The U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee held a joint meeting primarily focused on reviewing the cardiovascular safety of rosiglitazone, as presented by the FDA and GlaxoSmithKline. Following this two day discussion, Takeda Pharmaceuticals North America, Inc. ("Takeda") underscores its position that ACTOS (pioglitazone HCl) offers an established safety profile regarding the risk of CV events in people living with type 2 diabetes.

16 Jul 2010

Glaxo announces a $2.3 billion in legal liability charges

British pharmaceutical giant GlaxoSmithKline, announced this Thursday that its second-quarter charges related to legal cases involving the two drugs Avandia (diabetes drug) and Paxil (drug for anxiety and depression) would run up to $2.36 billion. Avandia’s use and its potential risk of causing heart problems were being debated this week by an advisory panel to the US Food & Drugs Administration (FDA).

16 Jul 2010

$235 million announced for expansion of biotech sector at CSL

A $235 million expansion of Australia's largest biotech facility in Melbourne is planned and this is expected to create hundreds of jobs. CSL biopharmaceutical research complex in Broadmeadows, in the north of Melbourne will be receiving this financial aid from both the State as well as Federal government over a five year investment plan. This will create an estimated 320 temporary construction jobs and later 333 new highly-skilled medical research openings by 2018.

15 Jul 2010

Access announces agreement to develop oral formulation of proprietary injectable drugs

Access Pharmaceuticals, Inc., announced today that it has entered into a pre-licensing feasibility agreement with a leading biotechnology company to develop an oral formulation of its currently-marketed, proprietary injectable drugs. Access will utilize its proprietary Cobalamin Oral Drug Delivery Technology to develop oral formulations of the drug for pre-clinical testing.

15 Jul 2010

NovaBay Pharmaceuticals issued Notice of Allowance for broad portfolio of anti-infective compounds

NovaBay Pharmaceuticals, Inc. announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office on a patent application for a broad portfolio of anti-infective compounds, including NVC-612. The patent will broaden protection for NovaBay's first-in-class Aganocide family of compounds, which are designed to fight infections without causing drug resistance.

15 Jul 2010

First Edition: July 15, 2010

Headlines topping today's news include reports about the White House release of new coverage rules for certain screening tests and other types of preventive care, and calls from the GOP for hearings on Berwick's recess appointment to run Medicare and Medicaid top today's news.

15 Jul 2010

Plexxikon announces promising preclinical data of PLX3397

Plexxikon Inc. today announced promising preclinical data from in vivo Alzheimer's Disease studies demonstrating a dramatic reduction in activated microglia in the brains of very old (22 months) 3xTG-AD mice, a triple transgenic model for Alzheimer's Disease. This reduction of activated microglia led to significantly improved learning in the treated group.

15 Jul 2010

Pharmaceutical News

Joint statement to help patients, physicians make informed decisions about use of rosiglitazone

Treatment admissions for abuse of prescription pain relievers increases by over 400%: Study

LLC to provide contract drug development services

FDA confirms GRAS status for Ajinomoto's AjiGRAS-Leucine

Steroid treatment can delay loss of kidney function

Diamyd Medical receives US Federal Trade Commission's antitrust clearance

Neurologists more aware of Merck Serono/EMD Serono's oral cladribine than Novartis/Mitsubishi Tanabe's FTY-720

First-of-its-kind patient, healthcare provider support program for management of HE

Federal advisory panel with reservations, recommends keeping Avandia on the Market

Columbia scientists discover new way to alleviate chronic pain

Judge says FTC likely overstepped authority in sharing drugmaker pay-for-delay info

Arsenic nanoparticle to combat aggressive type of breast cancer prevalent in young women

i26 hyperimmune egg balances improper immune inflammatory response

ACTOS offers safety profile regarding risk of CV events in people with type 2 diabetes: Takeda

Glaxo announces a $2.3 billion in legal liability charges

$235 million announced for expansion of biotech sector at CSL

Access announces agreement to develop oral formulation of proprietary injectable drugs

NovaBay Pharmaceuticals issued Notice of Allowance for broad portfolio of anti-infective compounds

First Edition: July 15, 2010

Plexxikon announces promising preclinical data of PLX3397

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News